Clinical Trials

Phase I trial initiated for AK receptor antagonist compound for severe pain, migraines

Published in Health and Medicine Week, December 19th, 2005

TorreyPines Therapeutics, Inc. announced that it has initiated a phase I clinical trial for NGX424, a novel therapeutic for the treatment of severe migraine and other persistent, intractable pain states. An AMPA/kainate (AK) receptor antagonist, NGX424 offers a non-opioid, non-vascular approach to the management of severe pain.

The phase I trial with NGX424 will enroll approximately 90 healthy male volunteers at one center in the U.S. The single, ascending, fixed-dose, study will evaluate the local and systemic tolerability, safety and pharmacokinetics of the drug, as well as the maximum tolerated dose of a subcutaneous formulation.

In previously...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2005-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry